Outside Pressures Threaten FDA Effectiveness, Gottlieb Says
Executive Summary
Payers are pushing for more comparative effectiveness studies, in part, because they know the more expensive and unwieldy studies will default to showing generics and branded drugs to be equal, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
You may also be interested in...
Comparative Effectiveness Funded By Public-Private Trust Proposed In House
Efforts to enhance the role and resources for research comparing the effectiveness of drugs and medical devices gained another boost May 7, with legislation introduced by Reps. Tom Allen, D-Maine, and Jo Ann Emerson, R-Mo
Medicare Bill Could Spur Interest In Drug Comparative Effectiveness Studies
Proposals to augment HHS studies comparing the effectiveness of drugs could gain ground thanks to provisions in Sen. Max Baucus' drug price negotiation legislation, regardless of the fate of price negotiation itself
Greater Regulation Of Pharma By Congress Could Be Risky – FDA’s Gottlieb
The push on Capitol Hill to increase regulation of the pharmaceutical industry may be a dangerous trend, FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb suggested